Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STAT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STAT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/STAT2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STAT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STAT2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STAT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:003434013 | Esophagus | ESCC | response to type I interferon | 48/8552 | 58/18723 | 6.18e-09 | 1.26e-07 | 48 |
GO:00603375 | Esophagus | ESCC | type I interferon signaling pathway | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
GO:00713575 | Esophagus | ESCC | cellular response to type I interferon | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
GO:000283212 | Esophagus | ESCC | negative regulation of response to biotic stimulus | 72/8552 | 108/18723 | 8.36e-06 | 8.11e-05 | 72 |
GO:00019595 | Esophagus | ESCC | regulation of cytokine-mediated signaling pathway | 95/8552 | 150/18723 | 9.48e-06 | 9.04e-05 | 95 |
GO:00603385 | Esophagus | ESCC | regulation of type I interferon-mediated signaling pathway | 29/8552 | 36/18723 | 1.91e-05 | 1.67e-04 | 29 |
GO:00450885 | Esophagus | ESCC | regulation of innate immune response | 125/8552 | 218/18723 | 3.34e-04 | 1.96e-03 | 125 |
GO:00507775 | Esophagus | ESCC | negative regulation of immune response | 112/8552 | 194/18723 | 4.67e-04 | 2.62e-03 | 112 |
GO:000268316 | Esophagus | ESCC | negative regulation of immune system process | 231/8552 | 434/18723 | 8.48e-04 | 4.36e-03 | 231 |
GO:00458245 | Esophagus | ESCC | negative regulation of innate immune response | 45/8552 | 71/18723 | 1.98e-03 | 8.90e-03 | 45 |
GO:00002662 | Esophagus | ESCC | mitochondrial fission | 28/8552 | 42/18723 | 4.90e-03 | 1.89e-02 | 28 |
GO:00603392 | Esophagus | ESCC | negative regulation of type I interferon-mediated signaling pathway | 15/8552 | 20/18723 | 7.60e-03 | 2.71e-02 | 15 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05167210 | Oral cavity | LP | Kaposi sarcoma-associated herpesvirus infection | 84/2418 | 194/8465 | 6.66e-06 | 5.16e-05 | 3.33e-05 | 84 |
hsa0516221 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
hsa0516523 | Oral cavity | LP | Human papillomavirus infection | 121/2418 | 331/8465 | 8.00e-04 | 3.86e-03 | 2.49e-03 | 121 |
hsa0516122 | Oral cavity | LP | Hepatitis B | 65/2418 | 162/8465 | 9.31e-04 | 4.43e-03 | 2.86e-03 | 65 |
hsa0462121 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa0462521 | Oral cavity | LP | C-type lectin receptor signaling pathway | 43/2418 | 104/8465 | 3.33e-03 | 1.41e-02 | 9.06e-03 | 43 |
hsa0421714 | Oral cavity | LP | Necroptosis | 59/2418 | 159/8465 | 1.15e-02 | 3.91e-02 | 2.52e-02 | 59 |
hsa0517138 | Oral cavity | LP | Coronavirus disease - COVID-19 | 128/2418 | 232/8465 | 7.04e-18 | 2.34e-16 | 1.51e-16 | 128 |
hsa0516936 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0516434 | Oral cavity | LP | Influenza A | 80/2418 | 171/8465 | 2.56e-07 | 3.41e-06 | 2.20e-06 | 80 |
hsa0516034 | Oral cavity | LP | Hepatitis C | 73/2418 | 157/8465 | 1.14e-06 | 1.36e-05 | 8.74e-06 | 73 |
hsa0516737 | Oral cavity | LP | Kaposi sarcoma-associated herpesvirus infection | 84/2418 | 194/8465 | 6.66e-06 | 5.16e-05 | 3.33e-05 | 84 |
hsa0516231 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
hsa0516533 | Oral cavity | LP | Human papillomavirus infection | 121/2418 | 331/8465 | 8.00e-04 | 3.86e-03 | 2.49e-03 | 121 |
hsa0516131 | Oral cavity | LP | Hepatitis B | 65/2418 | 162/8465 | 9.31e-04 | 4.43e-03 | 2.86e-03 | 65 |
hsa0462131 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa0462531 | Oral cavity | LP | C-type lectin receptor signaling pathway | 43/2418 | 104/8465 | 3.33e-03 | 1.41e-02 | 9.06e-03 | 43 |
hsa0421715 | Oral cavity | LP | Necroptosis | 59/2418 | 159/8465 | 1.15e-02 | 3.91e-02 | 2.52e-02 | 59 |
hsa0517146 | Oral cavity | EOLP | Coronavirus disease - COVID-19 | 108/1218 | 232/8465 | 8.08e-33 | 2.61e-30 | 1.54e-30 | 108 |
hsa0516744 | Oral cavity | EOLP | Kaposi sarcoma-associated herpesvirus infection | 68/1218 | 194/8465 | 2.59e-13 | 2.09e-11 | 1.24e-11 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAT2 | SNV | Missense_Mutation | rs755127513 | c.2491G>A | p.Glu831Lys | p.E831K | P52630 | protein_coding | deleterious_low_confidence(0.01) | benign(0.303) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
STAT2 | SNV | Missense_Mutation | | c.404N>G | p.Glu135Gly | p.E135G | P52630 | protein_coding | tolerated(0.13) | benign(0.054) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
STAT2 | SNV | Missense_Mutation | | c.2403N>T | p.Glu801Asp | p.E801D | P52630 | protein_coding | tolerated_low_confidence(0.25) | benign(0.007) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
STAT2 | SNV | Missense_Mutation | | c.599N>G | p.Gln200Arg | p.Q200R | P52630 | protein_coding | tolerated(0.09) | probably_damaging(0.992) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
STAT2 | SNV | Missense_Mutation | novel | c.2527N>A | p.Asp843Asn | p.D843N | P52630 | protein_coding | deleterious_low_confidence(0) | benign(0.104) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STAT2 | insertion | In_Frame_Ins | novel | c.1120_1121insAAAGGAACAGGGGTTGGG | p.Arg374delinsGlnArgAsnArgGlyTrpGly | p.R374delinsQRNRGWG | P52630 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
STAT2 | SNV | Missense_Mutation | novel | c.1063G>A | p.Glu355Lys | p.E355K | P52630 | protein_coding | tolerated(0.14) | probably_damaging(0.953) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
STAT2 | SNV | Missense_Mutation | | c.613G>C | p.Glu205Gln | p.E205Q | P52630 | protein_coding | tolerated(0.17) | possibly_damaging(0.889) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STAT2 | SNV | Missense_Mutation | | c.2348N>T | p.Ser783Leu | p.S783L | P52630 | protein_coding | tolerated_low_confidence(0.25) | benign(0.003) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STAT2 | SNV | Missense_Mutation | | c.2309N>C | p.Val770Ala | p.V770A | P52630 | protein_coding | tolerated_low_confidence(0.81) | benign(0) | TCGA-HM-A3JK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |